Navigation Links
AcelRx Pharmaceuticals Reports First Quarter 2012 Financial Results
Date:5/8/2012

REDWOOD CITY, Calif., May 8, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the first quarter ended March 31, 2012.

Net loss for the first quarter of 2012 was $7.1 million, or $0.36 per share, compared with a net loss of $3.2 million, or $0.30 per share, for the first quarter of 2011.  Common shares used in calculating basic and diluted earnings per share were 19,607,483 for the first quarter of 2012 compared to 10,742,182 common shares for the first quarter of 2011.

During the first quarter of 2012, AcelRx recognized revenue of $329,000 resulting from reimbursement for work completed under a research grant from the US Army Medical Research and Material Command, or USAMRMC, for development of its ARX-04 product candidate, a Sufentanil NanoTab® for the treatment of moderate-to-severe acute pain. 

Research and development expenses for the quarter ended March 31, 2012 totaled $4.8 million, compared with $1.9 million for the quarter ended March 31, 2011.  The increase was primarily due to development expenses for ARX-01, the Sufentanil NanoTab PCA System, AcelRx's lead product candidate for the treatment of post-operative pain.  During the first quarter, AcelRx prepared for and initiated the first of three planned Phase 3 clinical trials, a randomized, double-blind, placebo-controlled efficacy and safety trial in adults with post-operative pain, following open-abdominal surgery.  In April 2012, AcelRx initiated the second ARX-01 Phase 3 study, a randomized, open-label, parallel-group comparison of the efficacy and safety of the Sufentanil NanoTab PCA System to the standard of care, IV PCA with morphine, in t
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
2. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
3. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
4. AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
5. AcelRx to Present at the Lazard 6th Annual Healthcare Conference
6. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
7. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
8. AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
9. AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
10. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results
11. AcelRx Pharmaceuticals to Present at the JMP Securities Research Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Medical, Inc. (Nasdaq: NXTM ), a leading manufacturer ... Burbank , Chief Executive Officer, and Mathew Towse , ... Annual Canaccord Genuity Growth Conference being held at the InterContinental ... 13 th at 4:30 p.m. ET.  A webcast of ... About NxStage Medical NxStage Medical, ...
(Date:8/1/2014)... , Aug. 1, 2014  Neuland Laboratories Ltd., ... active pharmaceutical ingredients (APIs), complex intermediates and ... in 85 countries, today announced financial results for ... ended June 30, 2014. "Neuland,s results ... flow re-prioritization to accommodate certain customer needs, and ...
(Date:8/1/2014)... Aug. 1, 2014 Dyadic International, Inc. ("Dyadic") ... proprietary technologies are used to develop, manufacture and sell ... biopharmaceutical and industrial enzyme industries, announced today that it ... ended June 30, 2014 after market close on Thursday, ... that day at 5:00 p.m. Eastern Time to discuss ...
Breaking Medicine Technology:NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 2Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 3Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 3
... Second Generation Oxazolidinone Demonstrates Safety and Efficacy with Once-Daily, ... of Treatment , , SAN DIEGO, June ... its Phase 2 clinical trial evaluating the safety and ... the treatment of severe complicated skin and skin structure ...
... sets to be released-- , , PARIS, ... in patients with blepharospasm and cervical dystonia -- one placebo-controlled ... presented at the Movement Disorder Society (MDS) 13th annual International ... Pharmaceuticals, which plans to file a Biologic License Application (BLA) ...
Cached Medicine Technology:Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections 2Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections 3Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections 4Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 2Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 3Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 4
(Date:8/1/2014)... Summer is here, and with it comes the ... and they can be a pain for dogs. Animal Emergency ... their customers get rid of ticks and prevent them completely. ... the summer, which is why they are so active during ... woodland areas and carry a number of diseases, including lyme ...
(Date:8/1/2014)... a cancer diagnosis may improve health outcomes for Asian-American ... a researcher at the University of Houston (UH). ... is the writing instruction. Otherwise, writing is just like ... can be therapeutic, but oftentimes we don,t get the ... said Qian Lu, assistant professor and director of the ...
(Date:8/1/2014)... Hawley, PA (PRWEB) August 01, 2014 Hot ... in the destination spa category of the World’s Best ... kicks off a month-long celebration of National Relaxation Day (technically ... together a series of MAJOR experts to help guests celebrate ... how important it is for health and wellness to carve ...
(Date:8/1/2014)... HealthDay Reporter FRIDAY, Aug. ... as a time-honored destination for a good cut and conversation. ... also be the spot to tackle an often overlooked health ... novel partnership, the U.S. Centers for Disease Control and Prevention, ... the help of barbershop staff to both discuss and diagnose ...
(Date:8/1/2014)... Abington, PA (PRWEB) August 01, 2014 ... beneficial than bottle-feeding. A recent study conducted ... may not lag too far behind in terms of ... simply want to know what’s best for their baby. ... , According to Dr. Steven Shapiro , chair ...
Breaking Medicine News(10 mins):Health News:Tis the Season for Tick Prevention 2Health News:Expressive writing may help breast cancer survivors 2Health News:Expressive writing may help breast cancer survivors 3Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 2Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 3Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 4Health News:Barbershops Join Fight Against High Blood Pressure in Black Men 2Health News:Barbershops Join Fight Against High Blood Pressure in Black Men 3Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 2Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 3
... change your genes, say researchers after success in a ... McGill University in Montreal have found that nutrients // ... certain genes in rodents, reports science portal EurekAlert., ... a two-year-old study, which showed that the activity of ...
... for losing teeth as is generally known, but there ... said study author Dr. Khalaf F. Al-Shammari, of Kuwait ... educating the public about these factors that appear to ... increased attention to avoiding such factors.' Al-Shammari and colleagues ...
... first Phase III study involving the use of Actemra ... it is superior to conventional treatment modality that uses ... destruction. It has also been found to provide symptomatic ... arthritis is a debilitating autoimmune disease in which the ...
... Recent research conducted at the Ohio State University shows ... of cancer deaths involves the loss of an essential ... muscular // dystrophy. , ,The study findings, which ... Cell, show that muscle cells lose significant amounts of ...
... Thousands of patients in the United Kingdom may be at ... A poll ,conducted by a team of researchers randomly on ... of their // patients were overdosing on vitamins and remained ... , ,A large number of patients were ignorant about ...
... loss of virginity affects men and women across the spectrum is ... First Sexual Experiences. This is the first book of its kind ... the most important events in life. We all read and hear ... sex, but it doesn't tell us what losing their virginity means ...
Cached Medicine News:Health News:Food Habits Could Change Your Genes 2Health News:Novel Actemra monotherapy in treating patients with early aggressive rheumatoid arthritis 2Health News:Loss Of Dystrophin: Common Thread In Cancer And MS Muscle Wasting 2Health News:Vitamin Abuse Syndrome In the UK 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: